Clinical Trials
11 trialsNCT05576909 2023-07-13
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Beijing Tsinghua Chang Gung Hospital
Phase 2 Unknown
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04472858 2022-11-29
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Unknown
NCT05350943 2022-10-18
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Fudan University
Phase 2 Unknown
NCT05545124 2022-09-19
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Phase 2 Unknown
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05166772 2021-12-22
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05161143 2021-12-17
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05138159 2021-11-30
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Fudan University
Phase 2 Unknown
NCT04979663 2021-08-09
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
Fudan University
Phase 1/2 Unknown
NCT04059874 2019-08-16
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown